Members of the ASCRS Cornea Clinical Committee performed a review of the current literature on the corneal crosslinking (CXL) procedure for treating corneal ectasia. The members explored the data on the techniques currently in use and under investigation, including their advantages, safety profiles, risks, and cost analyses, compared with data on corneal transplantation. They concluded that CXL limits the progression of keratoconus, thus reducing the need for transplantation. They also found that compared with permitting the disease to progress naturally, CXL techniques carry significant and long-term cost and safety benefits, primarily by reducing the need for corneal transplantation. Studies of various CXL techniques (eg, epithelium-on treatment, changes in ultraviolet light parameters, riboflavin composition) continue with the ultimate goal of improving the procedure's safety and efficacy.

中文翻译：

---

角膜交联：当前协议和临床方法。

ASCRS角膜临床委员会的成员对有关治疗角膜扩张的角膜交联（CXL）程序的最新文献进行了回顾。成员们探索了与角膜移植数据相比，目前正在使用和正在研究的技术数据，包括其优势，安全性，风险和成本分析。他们得出的结论是，CXL限制了圆锥角膜的进展，从而减少了对移植的需求。他们还发现，与允许疾病自然发展相比，CXL技术主要通过减少对角膜移植的需求，具有明显的长期成本和安全性收益。研究各种CXL技术（例如上皮治疗，紫外线参数的变化，